TR&D2:BrainStructureandFunction P.I: John Detre, MD Co-Investigators: Brian Avants, PhD and Ze Wang, PhD ABSTRACT TRD2 focuses on neuroimaging methods for use in basic and clinical neuroscience. Much of this work concerns the development and application of arterial spin labeled (ASL) perfusion MRI, a method initiated by our Regional Resource (1). ASL provides noninvasive quantification of tissue perfusion (blood flow). In brain, cerebral blood flow (CBF) quantifies cerebrovascular function, but CBF also serves as a means of quantifying neural function more generally through the tight coupling between CBF and regional neural activity (2, 3). Over the past project period, TRD2 further developed ASL MRI technologies and applications at 3T and at 7T. Additional neuroimaging technology developed by TRD2 included imaging of myelin and myelin water, susceptibility weighted imaging, and the development of new signal-processing strategies for both functional and structural MRI of the brain. TRD2 also collaborated with TRD1 on metabolic imaging of the brain and with TRD4 on optical monitoring of CBF and metabolism in the brain. In the upcoming grant period, we plan to continue these lines of inquiry, and to collaborate with TRD3 on short-TE imaging.

Public Health Relevance

Neuroimaging methods allow brain structure and function to be measured noninvasively, and have become increasingly important as biomarkers for brain disorders and their treatment. This project focuses on the development and validation of quantitative cerebral blood flow and other biomarkers for use in clinical and translational research on the brain and its disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Biotechnology Resource Grants (P41)
Project #
5P41EB015893-34
Application #
9515578
Study Section
Special Emphasis Panel (ZEB1)
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
34
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Hua-Shan; Jawad, Abbas F; Laney, Nina et al. (2018) Effect of blood T1 estimation strategy on arterial spin labeled cerebral blood flow quantification in children and young adults with kidney disease. J Neuroradiol :
Liu, Hua-Shan; Hartung, Erum A; Jawad, Abbas F et al. (2018) Regional Cerebral Blood Flow in Children and Young Adults with Chronic Kidney Disease. Radiology 288:849-858
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Pang, Henry; Bow, Cora; Cheung, Jason Pui Yin et al. (2018) The UTE Disc Sign on MRI: A Novel Imaging Biomarker Associated With Degenerative Spine Changes, Low Back Pain, and Disability. Spine (Phila Pa 1976) 43:503-511
Busch, David R; Balu, Ramani; Baker, Wesley B et al. (2018) Detection of Brain Hypoxia Based on Noninvasive Optical Monitoring of Cerebral Blood Flow with Diffuse Correlation Spectroscopy. Neurocrit Care :
Li, Zhengjun; Vidorreta, Marta; Katchmar, Natalie et al. (2018) Effects of resting state condition on reliability, trait specificity, and network connectivity of brain function measured with arterial spin labeled perfusion MRI. Neuroimage 173:165-175
Parthasarathy, Ashwin B; Gannon, Kimberly P; Baker, Wesley B et al. (2018) Dynamic autoregulation of cerebral blood flow measured non-invasively with fast diffuse correlation spectroscopy. J Cereb Blood Flow Metab 38:230-240
Elbejjani, Martine; Auer, Reto; Dolui, Sudipto et al. (2018) Cigarette smoking and cerebral blood flow in a cohort of middle-aged adults. J Cereb Blood Flow Metab :271678X18754973
Nanga, Ravi Prakash Reddy; DeBrosse, Catherine; Kumar, Dushyant et al. (2018) Reproducibility of 2D GluCEST in healthy human volunteers at 7 T. Magn Reson Med 80:2033-2039
Cochran, Jeffrey M; Busch, David R; Leproux, Anaïs et al. (2018) Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. J Biomed Opt 24:1-11

Showing the most recent 10 out of 139 publications